Advertisement
Screener

Bluejay Diagnostics, Inc. (BJDX) Increase (Decrease) in Accrued Liabilities

2.8 / 5 stars · 68/120 Roast Me

Bluejay Diagnostics, Inc. Increase (Decrease) in Accrued Liabilities

Bluejay Diagnostics, Inc. (BJDX) reported Increase (Decrease) in Accrued Liabilities of $336.62 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-20.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2023-03-20

  • Bluejay Diagnostics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2022-12-31 was -$113.46K.
  • Bluejay Diagnostics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2022-09-30 was $207.14K, a 1.40% increase year-over-year.
  • Bluejay Diagnostics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2022-06-30 was $137.71K, a 99.94% increase year-over-year.
  • Bluejay Diagnostics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2022-03-31 was $105.22K, a 1213.97% increase year-over-year.
  • Bluejay Diagnostics, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $336.62K, a 64.33% increase from fiscal 2021.
  • Bluejay Diagnostics, Inc. increase (decrease) in accrued liabilities for fiscal 2021 was $204.84K, a 34.00% increase from fiscal 2020.
  • Bluejay Diagnostics, Inc. increase (decrease) in accrued liabilities for fiscal 2020 was $152.87K.
Period endIncrease (Decrease) in Accrued Liabilities 3 monthIncrease (Decrease) in Accrued Liabilities 6 monthIncrease (Decrease) in Accrued Liabilities 9 monthIncrease (Decrease) in Accrued Liabilities 12 month
2022-12-31-$113.46K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20
$93.68K
derived: sum of 2 quarters · filed 2023-03-20
$231.40K
derived: sum of 3 quarters · filed 2023-03-20
$336.62K
10-K · filed 2023-03-20
2022-09-30$207.14K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
$344.86K
derived: sum of 2 quarters · filed 2022-11-09
$450.08K
10-Q · filed 2022-11-09
$373.75K
derived: sum of 4 quarters · filed 2023-03-20
2022-06-30$137.71K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10
$242.94K
10-Q · filed 2022-08-10
$166.61K
derived: sum of 3 quarters · filed 2023-03-20
$370.89K
derived: sum of 4 quarters · filed 2023-03-20
2022-03-31$105.22K
10-Q · filed 2022-05-09
$28.89K
derived: sum of 2 quarters · filed 2023-03-20
$233.18K
derived: sum of 3 quarters · filed 2023-03-20
$302.05K
derived: sum of 4 quarters · filed 2023-03-20
2021-12-31-$76.33K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20
$127.95K
derived: sum of 2 quarters · filed 2023-03-20
$196.83K
derived: sum of 3 quarters · filed 2023-03-20
$204.84K
10-K · filed 2023-03-20
2021-09-30$204.28K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
$273.16K
derived: sum of 2 quarters · filed 2022-11-09
$281.17K
10-Q · filed 2022-11-09
2021-06-30$68.88K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10
$76.89K
10-Q · filed 2022-08-10
2021-03-31$8.01K
10-Q · filed 2022-05-09
2020-12-31$152.87K
10-K · filed 2022-03-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
OSR Health, Inc. (OSRH)United States$0.004B-0.75
Adagio Medical Holdings, Inc. (ADGM)United States$0.004B
Autonomix Medical, Inc. (AMIX)United States$0.004B
AETHLON MEDICAL INC (AEMD)United States$0.005B
INTELLIGENT BIO SOLUTIONS INC. (INBS)United States$0.005B
Beyond Air, Inc. (XAIR)United States$0.003B-0.01
Vivos Therapeutics, Inc. (VVOS)United States$0.003B-0.26
Sonoma Pharmaceuticals, Inc. (SNOA)United States$0.006B-2.59
NEXGEL, INC. (NXGL)United States$0.002B
INVO Fertility, Inc. (IVF)United States$0.002B-0.71